187 related articles for article (PubMed ID: 21889589)
1. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
[TBL] [Abstract][Full Text] [Related]
2. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.
Kranendijk M; Struys EA; van Schaftingen E; Gibson KM; Kanhai WA; van der Knaap MS; Amiel J; Buist NR; Das AM; de Klerk JB; Feigenbaum AS; Grange DK; Hofstede FC; Holme E; Kirk EP; Korman SH; Morava E; Morris A; Smeitink J; Sukhai RN; Vallance H; Jakobs C; Salomons GS
Science; 2010 Oct; 330(6002):336. PubMed ID: 20847235
[TBL] [Abstract][Full Text] [Related]
3. Computational approach to unravel the impact of missense mutations of proteins (D2HGDH and IDH2) causing D-2-hydroxyglutaric aciduria 2.
Thirumal Kumar D; Jerushah Emerald L; George Priya Doss C; Sneha P; Siva R; Charles Emmanuel Jebaraj W; Zayed H
Metab Brain Dis; 2018 Oct; 33(5):1699-1710. PubMed ID: 29987523
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
5. Novel cases of D-2-hydroxyglutaric aciduria with IDH1 or IDH2 mosaic mutations identified by amplicon deep sequencing.
Nota B; Hamilton EM; Sie D; Ozturk S; van Dooren SJ; Ojeda MR; Jakobs C; Christensen E; Kirk EP; Sykut-Cegielska J; Lund AM; van der Knaap MS; Salomons GS
J Med Genet; 2013 Nov; 50(11):754-9. PubMed ID: 24049096
[TBL] [Abstract][Full Text] [Related]
6. Disease-related metabolites in culture medium of fibroblasts from patients with D-2-hydroxyglutaric aciduria, L-2-hydroxyglutaric aciduria, and combined D/L-2-hydroxyglutaric aciduria.
Struys EA; Verhoeven NM; Roos B; Jakobs C
Clin Chem; 2003 Jul; 49(7):1133-8. PubMed ID: 12816910
[TBL] [Abstract][Full Text] [Related]
7. Measurement of D: -2-hydroxyglutarate dehydrogenase activity in cell homogenates derived from D: -2-hydroxyglutaric aciduria patients.
Wickenhagen WV; Salomons GS; Gibson KM; Jakobs C; Struys EA
J Inherit Metab Dis; 2009 Apr; 32(2):264-8. PubMed ID: 19283509
[TBL] [Abstract][Full Text] [Related]
8. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Akbay EA; Moslehi J; Christensen CL; Saha S; Tchaicha JH; Ramkissoon SH; Stewart KM; Carretero J; Kikuchi E; Zhang H; Cohoon TJ; Murray S; Liu W; Uno K; Fisch S; Jones K; Gurumurthy S; Gliser C; Choe S; Keenan M; Son J; Stanley I; Losman JA; Padera R; Bronson RT; Asara JM; Abdel-Wahab O; Amrein PC; Fathi AT; Danial NN; Kimmelman AC; Kung AL; Ligon KL; Yen KE; Kaelin WG; Bardeesy N; Wong KK
Genes Dev; 2014 Mar; 28(5):479-90. PubMed ID: 24589777
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA).
Vissers LE; Fano V; Martinelli D; Campos-Xavier B; Barbuti D; Cho TJ; Dursun A; Kim OH; Lee SH; Timpani G; Nishimura G; Unger S; Sass JO; Veltman JA; Brunner HG; Bonafé L; Dionisi-Vici C; Superti-Furga A
Am J Med Genet A; 2011 Nov; 155A(11):2609-16. PubMed ID: 22025298
[TBL] [Abstract][Full Text] [Related]
11.
Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
[TBL] [Abstract][Full Text] [Related]
13. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
14. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
17. Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate.
Rakheja D; Boriack RL; Mitui M; Khokhar S; Holt SA; Kapur P
Tumour Biol; 2011 Apr; 32(2):325-33. PubMed ID: 21080253
[TBL] [Abstract][Full Text] [Related]
18. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
Elife; 2017 Jun; 6():. PubMed ID: 28653623
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
20. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]